Multicenter phase II trial of adjuvant S-1 plus Docetaxel for 6 months in patients with pathological stage III gastric cancer (OGSG1002)

A Phase II Trial of Trastuzumab Combined with Irinotecan in Patients with Advanced HER2-positive Chemo-refractory Gastric Cancer: OGSG1203 (HERBIS-5)

Effects of an oral elemental nutrition supplement in gastric cancer patients with adjuvant S-1 chemotherapy after gastrectomy: a phase II study (OGSG1108)

A phase II study to examine the effectiveness of nutritional support with elemental diet for stage II/III gastric cancer patients receiving adjuvant chemotherapy with S-1 (OGSG 1108)

Phase II study of S-1 plus docetaxel as first-line treatment for elderly patients with advanced gastric cancer (OGSG0902)

Randomized, open-label, phase II study comparing five-weekly S-1 plus cisplatin (SP) with triweekly capecitabine plus cisplatin (XP) in chemotherapy-naïve patients with HER2 negative advanced gastric cancer (AGC) (HERBIS-4A / OGSG 1105)

Randomized phase II study to compare docetaxel plus S-1 with cisplatin plus S-1 in advanced gastric cancer without measurable lesions (HERBIS-3)

A dose-finding study for irinotecan, cisplatin, and S-1 (IPS) in patients with advanced gastric cancer (HERBIS-4B / OGSG 1106)

A multicenter phase II trial of perioperative capecitabine plus oxaliplatin for clinical stage III gastric cancer (OGSG1601)

An Intergroup phase III trial of Ramucirumab plus Irinotecan in Third or more line Beyond Progression after Ramucirumab for advanced Gastric Cancer (RINDBeRG trial)